Home
>
US Stocks
>
Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. (IOVA)

$8.73

-0.01

(-0.11%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Iovance Biotherapeutics, Inc.

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 8.9%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 96.7%

Performance

  • $8.62
    $9.12
    $8.73
    downward going graph

    1.32%

    Downside

    Day's Volatility :5.54%

    Upside

    4.28%

    downward going graph
  • $5.28
    $13.44
    $8.73
    downward going graph

    39.52%

    Downside

    52 Weeks Volatility :60.71%

    Upside

    35.04%

    downward going graph

Returns

PeriodIovance Biotherapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
19.73%
0.7%
-6.8%
6 Months
36.35%
-8.3%
-6.0%
1 Year
36.99%
-1.9%
-4.6%
3 Years
-73.61%
25.3%
25.9%

Highlights

Market Capitalization
2.0B
Book Value
$2.97
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.82
PEG Ratio
0.0
Wall Street Target Price
22.38
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-34.24%
Return On Equity TTM
-67.55%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-407.7M
Diluted Eps TTM
-2.82
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.26
EPS Estimate Next Year
-1.53
EPS Estimate Current Quarter
-0.74
EPS Estimate Next Quarter
-0.64

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Iovance Biotherapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
16
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 156.36%

Current $8.73
Target $22.38

Technicals Summary

Sell

Neutral

Buy

Iovance Biotherapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
35.93%
36.35%
36.99%
-73.61%
-39.93%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
NA
NA
0.0
-2.26
-0.68
-0.34
0.0
2.97
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.
Buy
$2.0B
-39.93%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • State Street Corporation

    6.12%

  • Vanguard Group Inc

    6.04%

  • BlackRock Inc

    5.38%

  • Mhr Fund Management Llc

    5.35%

  • Perceptive Advisors LLC

    4.44%

  • venBio Select Advisor LLC

    3.13%

Corporate Announcements

  • Iovance Biotherapeutics, Inc. Earnings

    Iovance Biotherapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.

Organization
Iovance Biotherapeutics, Inc.
Employees
503
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Industry
Health Technology

Discover More

FAQs